09:02 AM EDT, 05/15/2024 (MT Newswires) -- Immutep ( IMMP ) said Wednesday that the safety lead-in phase of the phase 2/3 trial of a breast cancer therapy yielded "encouraging" efficacy, safety and pharmacodynamic data.

The lead-in showed that the first-ever 90 mg dosing of eftilagimod alpha in combination with weekly paclitaxel remains well-tolerated with a favorable safety profile, the company said.

Immutep ( IMMP ) said a patient diagnosed with triple-negative breast carcinoma in 2019 and has failed various lines of therapy achieved a complete response, which has been maintained since stopping paclitaxel and being treated with eftilagimod alpha monotherapy.

Immutep ( IMMP ) shares rose 6.2% in premarket activity.

Price: 3.1126, Change: +0.18, Percent Change: +6.23